4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
11.99
+0.34 (2.92%)
Aug 14, 2026, 3:44 PM EDT - Market open
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, 4D Molecular Therapeutics stock has a consensus rating of "Buy" and an average price target of $29.1. The average 1-year stock price forecast is 142.70% higher than the current stock price, while the lowest is $18 (+50.13%) and the highest is $37 (+208.59%).
Price Target: $29.1 (+142.70%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 14, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +191.91% | Aug 14, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $36 | Buy | Reiterates | $36 | +200.25% | Aug 14, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 14, 2026 |
Financial Forecast
Revenue This Year
11.78M
from 85.21M
Decreased by -86.17%
Revenue Next Year
17.62M
from 11.78M
Increased by 49.54%
EPS This Year
-3.95
from -2.42
EPS Next Year
-3.83
from -3.95
EPS and Forward PE are based on non-GAAP adjusted numbers.